UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(RULE 14a-101)
INFORMATION REQUIRED IN
PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. __)


Filed by the Registrant \boxtimes

(4)

Date Filed:

Filed by a Party other than the Registrant \Box

Check the appropriate box: Preliminary Proxy Statement П Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) **Definitive Proxy Statement** X Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 Salarius Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. П Title of each class of securities to which transaction applies: (1) (2) Aggregate number of securities to which transaction applies: Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (3) (4)Proposed maximum aggregate value of transaction: (5) Total fee paid: Fee paid previously with preliminary materials. П Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. Amount Previously Paid: Form, Schedule or Registration Statement No.: (2) Filing Party: (3)



Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:

The Notice and Proxy Statement and Annual Report are available at www.proxyvote.com

SALARIUS PHARMACEUTICALS, INC. Annual Meeting of Stockholders June 16, 2021 10:00 AM CT This proxy is solicited by the Board of Directors

The undersigned hereby appoints David J. Arthur and Mark J. Rosenblum, or either of them, as proxy holders each with full power of substitution, to appear on behalf and to vote all shares of common stock of Salarius Pharmaceuticals, inc. (the "Company") that the undersigned is entitled to vote at the Annual Meeting of Stockholders of the Company to be held virtually via live webcast at www.virtualshareholdermeeting.com/SLRX2021 on June 16, 2021, and at any adjournment or postponement thereof.

When properly executed, this proxy will be voted as directed. If properly executed and no instructions are specified, this proxy will be voted FOR the election of the listed Nominees as Class III Directors under Proposal 1, FOR Proposals 2 and 3 and 1 YEAR for Proposal 4, and at the discretion of the proxies with respect to such other business as may properly come before the meeting. The proxies, in their discretion, are further authorized to vote (a) for the election of a person to the Board of Directors if any nominee named herein becomes unable to serve or for good cause will not serve, (b) on any matter which the Board of Directors id not know would be presented at the Annual Meeting of Stockholders by a reasonable time before the proxy solicitation was made, and (c) on other matters which may properly come before the Annual Meeting of Stockholders and any adjournments or postponements thereof.

This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of

Continued and to be signed on reverse side